ARCT
Arcturus Therapeutics Holdings Inc.
$9.97
+$0.34(+3.53%)
38
Overall
60
Value
25
Tech
31
Quality
Market Cap
$268.29M
Volume
929.55K
52W Range
$8.04 - $24.17
Target Price
$58.11
Order:
Income Statement
| Metric | Trend | Chart | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||
| Total Revenue | $20.8M | $9.5M | $12.4M | $206.0M | $166.8M | $152.3M | ||
| Total Revenue | $20.8M | $9.5M | $12.4M | $205.8M | $166.8M | $138.4M | ||
| GROSS PROFIT | ||||||||
| Gross Profit | $20.8M | $9.5M | $12.4M | $205.8M | $166.8M | $152.3M | ||
| OPERATING EXPENSES | ||||||||
| Operating Expenses | $46.3M | $81.1M | $215.2M | $193.6M | $245.0M | $248.0M | ||
| Research & Development | $33.6M | $57.8M | $173.8M | $147.8M | $192.1M | $195.2M | ||
| Research Expense | $33.6M | $57.8M | $173.8M | $147.8M | $192.1M | $195.2M | ||
| Selling, General & Administrative | $12.7M | $23.2M | $41.5M | $46.1M | $52.9M | $52.8M | ||
| General & Administrative Expenses | $12.7M | $23.2M | $41.5M | $46.1M | $52.9M | $52.8M | ||
| Salaries & Wages | -- | -- | -- | $30.6M | $34.6M | $38.0M | ||
| Depreciation & Amortization | $684.0K | $900.0K | $1.2M | $1.5M | $3.0M | $3.5M | ||
| Depreciation & Amortization | $684.0K | $900.0K | $1.2M | $1.5M | $3.0M | $3.5M | ||
| Other Operating Expenses | $1.2M | $-800.0K | $-1.0M | $-1.0M | $-600.0K | $-2.0M | ||
| OPERATING INCOME | ||||||||
| Operating income | $-25.5M | $-71.5M | $-202.9M | $12.2M | $-78.2M | $-95.7M | ||
| EBITDA | $-24.4M | $-70.4M | $-201.7M | $15.2M | $-24.9M | $-77.4M | ||
| NON-OPERATING ITEMS | ||||||||
| Interest Expense (Non-Operating) | $900.0K | $831.0K | $2.7M | $3.0M | $767.0K | -- | ||
| Net Non-Operating Interest Income/Expense | $-900.0K | $-900.0K | $-800.0K | $420.0K | $-16.6M | -- | ||
| Other Income/Expense | $478.0K | $624.0K | $1.4M | $-1.1M | $-50.5M | $-15.2M | ||
| Other Special Charges | $-446.0K | $-361.0K | $-1.9M | $-420.0K | $50.5M | $15.2M | ||
| PRE-TAX INCOME | ||||||||
| EBIT | $-25.1M | $-71.3M | $-202.9M | $13.6M | $-27.9M | $-80.9M | ||
| Pre-Tax Income | $-26.0M | $-72.1M | $-203.7M | $10.6M | $-27.9M | $-80.9M | ||
| INCOME TAX | ||||||||
| Tax Provision | -- | -- | -- | $1.3M | $1.8M | $-4.0K | ||
| NET INCOME | ||||||||
| Net Income | $-26.0M | $-72.1M | $-203.7M | $9.3M | $-29.7M | $-80.9M | ||
| Net Income (Continuing Operations) | $-26.0M | $-72.1M | $-203.7M | $9.3M | $-29.7M | $-80.9M | ||
| Net Income (Discontinued Operations) | $-26.0M | $-72.1M | $-203.7M | $9.3M | $-29.7M | $-80.9M | ||
| Net Income (Common Stockholders) | $-26.0M | $-72.1M | $-203.7M | $9.3M | $-29.7M | $-80.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-80.9M | ||
| TOTALS | ||||||||
| Total Expenses | $46.3M | $81.1M | $215.2M | $193.6M | $245.0M | $248.0M | ||
| SHARE & EPS DATA | ||||||||
| Average Shares Outstanding | $12.1M | $20.3M | $26.3M | $26.4M | $26.6M | $27.0M | ||
| Average Shares Outstanding (Diluted) | $12.1M | $20.3M | $26.3M | $27.1M | $26.6M | $27.0M | ||
| Shares Outstanding | $15.1M | $26.3M | $26.4M | $26.6M | $26.9M | $27.1M | ||
| Basic EPS | $-2.15 | $-3.55 | $-7.74 | $0.35 | $-1.12 | $-3 | ||
| Basic EPS (Continuing Operations) | $-2.15 | $-3.55 | $-7.74 | $0.35 | $-1.12 | $-3 | ||
| Diluted EPS | $-2.15 | $-3.55 | $-7.74 | $0.35 | $-1.12 | $-3 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $0.35 | $-1.12 | $-3 | ||
| OTHER METRICS | ||||||||
| Earnings from equity interest | $-32.0K | $-263.0K | $515.0K | $-515.0K | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $-32.0K | $-263.0K | $515.0K | $-515.0K | -- | -- | ||
| Other Gand A | $12.7M | $23.2M | $41.5M | $46.1M | $52.9M | $52.8M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARCT | $9.97 | +3.5% | 929.55K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arcturus Therapeutics Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW